Kyung Dong Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Kyung Dong Pharmaceutical's earnings have been declining at an average annual rate of -39.4%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 0.4% per year.
Key information
-39.4%
Earnings growth rate
-41.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | -0.4% |
| Return on equity | -7.4% |
| Net Margin | -9.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend
Feb 18
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?
Feb 03Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?
Dec 20We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05Revenue & Expenses Breakdown
How Kyung Dong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 178,594 | -16,191 | 91,940 | 14,841 |
| 31 Mar 24 | 170,232 | -18,920 | 88,365 | 14,704 |
| 31 Dec 23 | 162,674 | -20,708 | 86,471 | 13,827 |
| 30 Sep 23 | 165,709 | 6,480 | 81,024 | 13,189 |
| 30 Jun 23 | 174,143 | 8,366 | 76,385 | 13,287 |
| 31 Mar 23 | 173,109 | 8,422 | 74,423 | 11,951 |
| 31 Dec 22 | 182,718 | 12,161 | 70,602 | 12,618 |
| 30 Sep 22 | 181,798 | 6,506 | 71,897 | 12,469 |
| 30 Jun 22 | 183,683 | 9,179 | 71,610 | 12,137 |
| 31 Mar 22 | 185,793 | 12,291 | 70,198 | 11,813 |
| 31 Dec 21 | 177,611 | 12,672 | 68,444 | 10,537 |
| 30 Sep 21 | 175,894 | 13,577 | 68,557 | 10,877 |
| 30 Jun 21 | 172,332 | 11,669 | 68,380 | 10,146 |
| 31 Mar 21 | 171,853 | 11,087 | 67,694 | 9,767 |
| 31 Dec 20 | 173,828 | 12,459 | 66,540 | 10,063 |
| 30 Sep 20 | 175,091 | 12,916 | 66,130 | 9,818 |
| 30 Jun 20 | 174,263 | 18,549 | 66,506 | 9,490 |
| 31 Mar 20 | 176,348 | 20,788 | 66,537 | 9,589 |
| 31 Dec 19 | 176,500 | 20,126 | 67,737 | 8,918 |
| 30 Sep 19 | 175,906 | 5,751 | 66,891 | 8,262 |
| 30 Jun 19 | 177,842 | 3,155 | 65,915 | 7,142 |
| 31 Mar 19 | 175,602 | 3,193 | 65,379 | 6,274 |
| 31 Dec 18 | 179,316 | 5,242 | 64,551 | 5,869 |
| 30 Sep 18 | 180,112 | 16,912 | 64,745 | 5,510 |
| 30 Jun 18 | 181,528 | 18,700 | 65,165 | 5,626 |
| 31 Mar 18 | 181,861 | 20,562 | 64,513 | 5,778 |
| 31 Dec 17 | 177,772 | 20,477 | 64,265 | 5,648 |
| 30 Sep 17 | 173,022 | 22,222 | 62,876 | 5,667 |
| 30 Jun 17 | 166,640 | 19,444 | 61,880 | 5,735 |
| 31 Mar 17 | 162,703 | 18,670 | 61,794 | 5,336 |
| 31 Dec 16 | 158,599 | 17,609 | 61,226 | 5,033 |
| 30 Sep 16 | 155,705 | 18,629 | 60,411 | 5,090 |
| 30 Jun 16 | 153,079 | 13,673 | 63,410 | 5,061 |
| 31 Mar 16 | 150,793 | 13,928 | 60,436 | 5,956 |
| 31 Dec 15 | 151,893 | 14,132 | 60,524 | 5,156 |
| 30 Sep 15 | 153,195 | 15,395 | 55,793 | 7,783 |
| 30 Jun 15 | 151,288 | 22,404 | 50,023 | 6,758 |
| 31 Mar 15 | 153,286 | 22,924 | 50,153 | 4,747 |
| 31 Dec 14 | 153,260 | 24,518 | 48,253 | 4,771 |
| 30 Sep 14 | 151,581 | 23,891 | 48,520 | 4,226 |
| 30 Jun 14 | 148,236 | 25,787 | 47,853 | 4,229 |
| 31 Mar 14 | 140,863 | 24,591 | 46,608 | 4,232 |
| 31 Dec 13 | 133,074 | 18,852 | 44,547 | 4,231 |
Quality Earnings: A011040 is currently unprofitable.
Growing Profit Margin: A011040 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A011040 is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.
Accelerating Growth: Unable to compare A011040's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A011040 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
Return on Equity
High ROE: A011040 has a negative Return on Equity (-7.42%), as it is currently unprofitable.